RxSight

3800 N Central Ave Ste 460, Phoenix, Arizona, United States374 employees

Also known as:

rxst-us

rxst

rxsight, inc.

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

55.6%

Trial Status Distribution

Completed

77.8%

Enrolling By Invitation

11.1%

Terminated

11.1%

Clinical Trials

Trials sponsored by this organization (9)

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

Enrolling By Invitation

observational

Nov 2025108 participants

RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

Not Applicable

Completed

interventional

Dec 2021500 participants

Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes

Completed

interventional

May 202079 participants

A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus

Terminated

interventional

Nov 201934 participants

A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

Not Applicable

Completed

interventional

Jul 201925 participants

Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery

Not Applicable

Completed

interventional

Aug 2018105 participants

Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism

Not Applicable

Completed

interventional

Jun 201855 participants

Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

Completed

interventional

Jun 201866 participants

Page 1 of 2

Approvals

No approval data available

News

RxSight Announces Preliminary Q2 2026 Results, Alcon Collaboration, and Next-Generation Light-Adjustable IOL Pipeline

- RxSight reported preliminary Q2 2026 total revenue of approximately $32–$34 million, including $5–$7 million from its newly announced strategic collaboration with Alcon. - The company sold 24,917 Light Adjustable Lens (LAL) units and placed 11 Light Delivery Devices (LDD) in the quarter, while facing what CEO Ron Kurtz described as "meaningful commercial headwinds." - RxSight unveiled a next-generation Light Adjustable Technology platform featuring new LAL, LAL+, and LAL Toric lenses with improved workflow and fewer post-operative treatments. - Full-year 2026 revenue guidance was revised to $140–$160 million, with product sales lowered to $110–$120 million and gross margin raised to 73%–75%.

Jul 6, 2026

Back to Organizations